anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: organic chemistry, chemical technology. SUBSTANCE: invention relates to a novel method for preparing biphenylisoxazole sulfonamide of the formula (I)  , its enantiomers and diastereomers and its salts where X means oxygen atom; Y means nitrogen atom; each of R 3 , R 4  is bound with directly with ring carbon and means independently alkyl; each of R 1 , R 2  is bound directly with ring carbon and means independently hydrogen atom or alkyl; each of R 11 , R 12 , R 13 , R 14  means independently hydrogen atom; J means oxygen atom; K means nitrogen atom; L means carbon atom; p = 0 or whole number from 1 to 2. Method involves: (a) interaction of pinacol ester of the formula (II)   with halogenphenyl compound of the formula (III)   in the presence of palladium (0) catalyst and, optionally, a base to yield nitrogen-protected derivative of the formula (IV)   and (b) removal of protective group at nitrogen atom in compound of the formula (IV) to yield compound of the formula (I). Invention relates also to pinacol ester of the general formula (II) where X means oxygen atom; Y means nitrogen atom where each of R 3 , R 4  is bound directly with ring carbon and means independently alkyl; each of R 13 , R 14  is bound with ring carbon and means independently hydrogen atom; "prot" means nitrogen-protective group. Invention relates also to method for preparing compound of the formula (II) involving: (a) interaction of compound of the formula (V)   with amine of the formula (VI)   in the presence of organic base and organic solvent to yield compound of the formula (VII)  ; (b) protection of nitrogen atom in indicated compound of the formula (VII) to yield compound of the formula (VIII)   given in the invention claim; (c) preparing lithium derivative of indicated compound of the formula (VIII) using alkyl- or aryllithium compound and the following reaction of formed lithium derivative with trialkylborate and the following hydrolysis to yield boronic acid of the formula (IX)  ; (d) interaction of indicated compound of the formula (IX) with pinacol, water removal to yield compound of the formula (II). Invention provides the novel method for preparing biphenylisoxazole sulfonamides. EFFECT: improved preparing method. 34 cl, 4 ex
Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
BACKGROUND: Bacterial wilt caused by Ralstonia solanacearum severely affects peanut (Arachis hypogaea L.) yields. The breeding of resistant cultivars is an efficient means of controlling plant diseases. Therefore, identification of resistance genes effective against bacterial wilt is a matter of urgency. The lack of a reference genome for a resistant genotype severely hinders the process of identification of resistance genes in peanut. In addition, limited information is available on disease resistance-related pathways in peanut.
RESULTS: Full-length transcriptome data were used to generate wilt-resistant and -susceptible transcript pools. In total, 253,869 transcripts were retained to form a reference transcriptome for RNA-sequencing data analysis. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of differentially expressed genes revealed the plant-pathogen interaction pathway to be the main resistance-related pathway for peanut to prevent bacterial invasion and calcium plays an important role in this pathway. Glutathione metabolism was enriched in wilt-susceptible genotypes, which would promote glutathione synthesis in the early stages of pathogen invasion. Based on our previous quantitative trait locus (QTL) mapping results, the genes arahy.V6I7WA and arahy.MXY2PU, which encode nucleotide-binding site-leucine-rich repeat receptor proteins, were indicated to be associated with resistance to bacterial wilt.
CONCLUSIONS: This study identified several pathways associated with resistance to bacterial wilt and identified candidate genes for bacterial wilt resistance in a major QTL region. These findings lay a foundation for investigation of the mechanism of resistance to bacterial wilt in peanut.
During the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1, Atezo on Day 1, and Pola on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months, during maintenance treatment for FL participants.
Elderly persons with mild cognitive impairment experience a cognitive decline that is confirmed by a neuropsychological examination but do not meet the clinical criteria for dementia. However, longitudinal studies have shown that up to 75% of these persons develop dementia of the Alzheimer type after 5 years of follow-up. A significant proportion of these persons are thus in a prodromal phase of the disease. This phase is likely to represent a key moment in which to apply appropriate interventions. Indeed, these persons have the cognitive capabilities to benefit from such interventions. Cognitive training has been shown to be effective in improving the memory function of older persons without cognitive decline and increasing evidence indicates that persons with MCI might also benefit from such interventions. However, there is few researches have focused on the Mild Cognitive Impairment population in spite of the fact that they are at-risk of experiencing significant cognitive problems in the next few years while still having the potential to benefit from non-pharmacological interventions. In a number of pilot studies, the investigators compared cognitive and psychosocial intervention to a control intervention in persons with MCI. The participants' performance improved on proximal outcomes and on distal outcomes (activities of daily living). The purpose of this project is to study the efficacy of the cognitive intervention in a larger group of participants, compare it with a non-cognitive intervention, assess the long term maintenance of the improvement and measure the potential implication of cognitive and psychosocial factors.

Persons with Mild Cognitive Impairment will first receive a comprehensive clinical assessment to determine whether they meet the research criteria for Mild Cognitive Impairment. They will then be randomly allocated to one of three groups. One group will receive cognitive training, one group will receive psychosocial intervention and one group will receive no intervention. The two interventions will be offered on a one-session per week basis during an 8-week period. The cognitive intervention will include training of attention and episodic memory. This intervention is based on recently acquired knowledge regarding the nature of the deficits in mild cognitive impairment as well as factors that are known to optimize memory. The psychosocial intervention will focus on goal management. Booster sessions will be offered to the intervention groups after 3 and 6 months. Each intervention will act as social contact control group for the other intervention. The third group will receive no intervention and will be used as a no-contact control group.

All groups will undergo one pre-intervention assessment (1-2 week before beginning of intervention), one post-intervention assessment (1-2 week after end of intervention) and additional assessments one week after before the booster sessions and nine month following end of training. This last assessment will measure long-term retention of training and will assess the degree of change in the clinical profile of patients.
TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Additional treatment was initiated in 1/3 of the cases. This was registered at the end-point interview.
A thermoplastic composition comprising a mixture of 50-90 per cent wax and 10-50 per cent blown vegetable oils is used for making the casting patterns which are employed in the manufacture of moulded articles such as dentures and rings and pins or other items of jewellery.  The wax may be candelilla wax, carnauba wax, beeswax, palm wax, bayberry wax, ouricoury wax, ceresin wax, or the amorphous, crystalline or microcrystalline type of paraffin wax and mixtures of waxes may be employed.  The blown oil may be derived from cashew shell oil, linseed oil, oiticica oil or chinawood oil and mixtures of blown oils may be employed. Fillers such as natural or synthetic resins, particularly rosin, dammar, melamine resins, phenolic resins, polystyrene or polymethyl methacrylate, may be incorporated in the composition. In the examples, compositions are described consisting of (a) blown linseed oil with candelilla wax, carnauba wax, microcrystalline wax, amorphous mineral wax, yellow beeswax or ceresin wax, (b) blown chinawood oil with candelilla wax, beeswax or ceresin wax, and (c) blown linseed oil with candelilla wax and amorphous wax, carnauba wax or rosin.  The Specification as open to inspection under Sect. 91 refers to a thermoplastic composition comprising an intermixture of wax and a polymerized vegetable oil miscible therewith.  This subject-matter does not appear in the Specification as accepted.ALSO:A thermoplastic composition comprising a mixture of 50 - 90 per cent wax and 10 - 50 per cent blown vegetable oil is used for making the casting patterns which are employed in the manufacture of moulded articles such as dentures and rings and pins or other items of jewellery.  The wax may be candelilla wax, carnauba wax, beeswax, palm wax, bayberry wax, ouricoury wax, ceresin wax or the amorphous crystalline or microcrystalline type of paraffin wax and mixtures of waxes may be employed.  The blown oil may be derived from cashew shell oil, linseed oil, oiticica oil or chinawood oil and mixtures of blown oils may be employed.  Fillers such as natural or synthetic resins, particularly rosin, dammar, melamine resins, phenolic resins, polystyrene or polymethyl methacrylate, may be incorporated in the composition.  In the examples, compositions are described consisting of (a) blown linseed oil with candelilla wax, carnauba wax, microcrystalline wax, amorphous mineral wax, yellow beeswax or ceresin wax, (b) blown china-wood oil with candelilla wax, beeswax or ceresin wax and (c) blown linseed oil with candelilla wax and omorphous wax, carnauba wax or rosin.  The Specification as open to inspection under Sect. 91 refers to a thermoplastic composition comprising an intermixture of wax and a polymerized vegetable oil miscible therewith.  This subject-matter does not appear in the Specification as accepted.
OBJECTIVE: To evaluate if berberine can act on vitamin D receptors (VDR) and thereby regulate the expression of tight junction proteins (TJPs) in irritable bowel syndrame-diarrhea-predominant (IBS-D) rats.
METHODS: The newborn rats were induced into IBS-D rat model via neonatal maternal separation combined with acetic acid chemical stimulation. After modeling, the model was evaluated and rats were divided into the control group and berberine treatment groups (0.85, 1.7 and 3.4 mg/kg, once a day for 2 weeks). The distal colon was obtained and colonic epithelial cells (CECs) were isolated and cultured after IBS-D model evaluation. The vitamin D receptor response element (VDRE) reporter gene was determined in the CECs of IBS-D rats to analyze the effect of berberine on the VDRE promoter. VDR overexpression or silencing technology was used to analyze whether VDR plays a role in promoting intestinal barrier repair, and to determine which region of VDR plays a role in berberine-regulated intestinal TJPs.
RESULTS: The IBS-D rat model was successfully constructed and the symptoms were improved by berberine in a dose-dependent manner (P<0.05). The activity of VDRE promoter was also effectively promoted by berberine (P<0.05). Berberine increased the expression of TJPs in IBS-D CECs (P<0.05). VDR expression was significantly increased after transfection of different domains of VDR when compared to normal control and basic plasmid groups (all P<0.05). RT-qPCR and Western blot results showed that compared with the blank group, expressions of occludin and zonula occludens-1 were significantly higher in VDR containing groups (all P<0.05). Berberine plus pCMV-Myc-VDR-N group exerted the highest expression levels of occludin and zonula occludens-1 (P<0.05).
CONCLUSION: Berberine enhances intestinal mucosal barrier function of IBS-D rats by promoting VDR activity, and the main site of action is the N-terminal region of VDR.
Patients receive cisplatin IV over 6 hours on day 1 following surgery. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally undergo blood sample collection on study.
Breastfeeding is the ideal source of nutrition for babies. The World Health Organization (WHO) recommends continuing breastfeeding exclusively with breast milk for the first 6 months and with complementary foods for up to 3 years. Breastfeeding is extremely effective on the health of the baby and mother. The aim of this study is to determine the effect of breastfeeding education and humor-based practices in the antenatal period on breastfeeding motivation and attachment. 32-36 patients who applied to Bartın Gynecology and Children's Hospital for the project. It will consist of 64 pregnant women (32 experimental and 32 control group) at gestational week. Pregnant women who agree to participate in the project between these months will receive 30-45 minutes of humor practice after 30 minutes of breastfeeding training in the first session. The education and humor application will be implemented again a week later, on the same day, at the same time and in the same place. In the humor application, dance performances, applause, singing and laughter accompanied by 5 songs determined by the researchers will be included. The training program prepared for breastfeeding education will be applied to pregnant women. Then, humor will be applied. A pre-test will be administered before the training, a mid-test 1 month after the training, and a post-test in the 3rd month. Project data will be collected using the 'Introductory Information Form', 'Breastfeeding Motivation Scale' and 'Maternal Attachment Scale'.
OBJECTIVE: Endometriosis is a disease in which stromal cells and endometrial glands extend outside of the uterine cavity. Nevertheless, treatment failure and recurrence cause difficulties in management. This study aimed to evaluate the receptor-level components of bilateral endometriomas in the recurrence state.
METHODS: Our retrospective cohort study was conducted with patients who underwent surgery for bilateral endometriomas between 2015 and 2021. In total, 113 patients were allocated. A total of 76 patients did not meet the eligibility criteria, and the data of 37 patients were evaluated. Medical treatments, recurrences, and postoperative follow-up data were collected. In archived tissue samples, measurements of progesterone receptor A and progesterone receptor B, histoscores and immunoreactivity scores, and their ratios were calculated in the group that received no postoperative medical treatment. Criteria for recurrence were a repeat operation and/or the detection of a new endometrioma>2 cm at the follow-up examination.
RESULTS: No recurrence was observed in 73.0% (n=27) of the cases, whereas recurrence was observed in 27.0% (n=10) of the participants. Patients without recurrence had significantly higher progesterone receptor B histoscore/progesterone receptor A histoscore and progesterone receptor B immunoreactivity score/progesterone receptor A immunoreactivity score results (p=0.01). Nevertheless, when the histoscores and immunoreactivity scores for both receptors were contrasted separately, there was no appreciable difference between them.
CONCLUSION: The dominance of progesterone receptor B over progesterone receptor A was inversely proportional to the recurrence status in bilateral endometriomas. Furthermore, our study revealed that assessing receptor levels alone did not result in a significant difference in recurrence.
An anti-aging soft capsule for women during menopause and a preparation method thereof are provided. The soft capsule is composed of a capsule content and a capsule shell. The capsule content is composed of soy isoflavone extract powder, pomegranate seed oil, Limonium bicoior extract, a suspending agent and a wetting agent. The capsule shell is made of gelatin, plasticizer, colorant and water. The colorant is composed of white pigment and milk chocolate brown pigment. The soft capsule has the functions of antioxidant and alleviating menopausal symptoms. Moreover, the soft capsule can supplement vital energy and nourish blood for women, enabling women to have rosy and shiny appearance, smooth and elastic skin, and improved physical fitness.
Pulse radiofrequency therapy will be applied to each nerve in 2 cycles of 120 seconds for patients in the pulse radiofrequency group. After the pulse radiofrequency procedure, 1 cc betamethasone and 1 cc 1% lidocaine will be injected for each nerve.
The present invention relates to a new injectable formulation of ramoplanin or a compound of the ramoplanin family. More particularly, the injectable formulations of the invention are particularly suitable for intravenous (i.v.) administration. They contain the active principle(s) in a fat emulsion product for i.v. administration. The formulations of the invention are well tolerated and are effective in particular in severe Gram positive infections.
BACKGROUND: Thyroid cancer represents the most prevalent malignant endocrine tumour, with rising incidence worldwide and high mortality rates among patients exhibiting dedifferentiation and metastasis. Effective biomarkers and therapeutic interventions are warranted in aggressive thyroid malignancies. The transcription factor 19 (TCF19) gene has been implicated in conferring a malignant phenotype in cancers. However, its contribution to thyroid neoplasms remains unclear.
RESULTS: In this study, we performed genome-wide and phenome-wide association studies to identify a potential causal relationship between TCF19 and thyroid cancer. Our analyses revealed significant associations between TCF19 and various autoimmune diseases and human cancers, including cervical cancer and autoimmune thyroiditis, with a particularly robust signal for the deleterious missense variation rs2073724 that is associated with thyroid function, hypothyroidism, and autoimmunity. Furthermore, functional assays and transcriptional profiling in thyroid cancer cells demonstrated that TCF19 regulates important biological processes, especially inflammatory and immune responses. We demonstrated that TCF19 could promote the progression of thyroid cancer in vitro and in vivo and the C>T variant of rs2073724 disrupted TCF19 protein binding to target gene promoters and their expression, thus reversing the effect of TCF19 protein.
CONCLUSIONS: Taken together, these findings implicate TCF19 as a promising therapeutic target in aggressive thyroid malignancies and designate rs2073724 as a causal biomarker warranting further investigation in thyroid cancer.
BACKGROUND: Hypothermia is a common perioperative problem that can lead to severe complications. We evaluated whether a heated mattress (HM) is superior to a warm air blanket (WA) in preventing perioperative hypothermia in patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA).
METHODS: A retrospective cohort study was performed in a teaching hospital and data were collected for all patients undergoing THA or TKA between January 1, 2015 and May 1, 2022. We used logistic and linear regressions to analyze hypothermia occurrence and important complications. Results were adjusted for confounders and time, and was present in all subgroups and after imputation of missing data.
RESULTS: In total, 4,683 of 5,497 patients had information on type of heating. We found more perioperative hypothermia in patients treated with an HM compared to a WA for both THA (odds ratio-adjusted 1.42 [1.0 to 1.6] P = .06) and TKA (odds ratio-adjusted 2.10 [1.5 to 3.0] P < .01). There was no difference in postoperative infections between groups (all between 0.5% and 1.3%). Patients who had an HM significantly stayed longer in the postoperative ward (a mean difference of 4 [TKA] to 6 [THA] minutes, P < .01), but there was no difference in hospital stay.
CONCLUSION: A WA is superior compared to an HM in preventing perioperative hypothermia, with no increased risk of complications. Patients who have an HM stayed longer at the postoperative ward, potentially because of higher hypothermia rates. Therefore, it is suggested to use a WA instead of an HM.
Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
A 65-year-old woman presented with unexplained weight loss, recurrent fever, and a dermatosis with painful nodules on the extremities. Biopsies showed focal lobular panniculitis with neutrophilic microgranulomas. Comprehensive investigations ruled out infection and hematologic and solid organ neoplasms. Laboratory results showed anti-Ro/SSA and anti-La/SSB antibody positivity, and elevated inflammatory markers. Dry mouth and eye were confirmed. The diagnosis of Sjögren syndrome with cutaneous panniculitis was established. Prednisone treatment with 30 mg/d resulted in remission of fever and pain improvement. This case emphasizes Sjögren syndrome as an autoimmune disease with multiple cutaneous manifestations and highlights its association with granulomatous panniculitis.
The healers will prepare before the start with prayer for connection with Good Spirits. Volunteers will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
Invention can be used for preparing the human neurotrophic growth factor (enovin/ENV). Isolated nucleic acid molecule is fused into the expressing vector. Vector or the growth factor (enovin/ENV) is used for preparing a pharmaceutical composition used for treatment and prophylaxis in disturbances in the nervous system. The growth factor is detected in sample using antibody that is able to bind with the growth factor. Identification of agonist or antagonist of the neurotrophic growth factor is carried out by interaction of biological material expressing the growth factor receptor with the analyzed compound in the presence of the indicated growth factor. Invention provides the development of medicinal agents used or prophylaxis and treatment of neurodegenerative diseases.